A Multi-center, Randomized, Open-label, Parallel-group Clinical Study to Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip) and Felodipine Sustained-Release Tablet for the Treatment of Patients With Mild-to-Moderate Hypertension

Trial Profile

A Multi-center, Randomized, Open-label, Parallel-group Clinical Study to Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip) and Felodipine Sustained-Release Tablet for the Treatment of Patients With Mild-to-Moderate Hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Felodipine (Primary) ; Lercanidipine (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Lee Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2013 Status changed from recruiting to completed, as reported in the Lees Pharmaceuticals Q1 report.
    • 17 Jul 2013 Results of this trial will be available in Q2 2013 according to the Lees Pharmaceuticals Q1 report.
    • 26 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top